Voyager Therapeutics Inc. held its annual meeting of stockholders on June 3, 2025. During the meeting, several proposals were voted on. Grace E. Colón, Ph.D., Catherine J. Mackey, Ph.D., Glenn Pierce, M.D., Ph.D., and George Scangos, Ph.D., were elected as Class I directors. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan were approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056835), on June 05, 2025, and is solely responsible for the information contained therein.